Yiqun Han1, Jiayu Wang1, Zijing Wang1, Binghe Xu1. 1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract
PURPOSE: To better understand the differences in clinicopathological features and prognosis between male breast cancer (MBC) and female breast cancer (FBC). MATERIAL AND METHODS: Data on patients diagnosed with breast cancer from January 1, 2010, to December 31, 2016, were obtained from the Surveillance, Epidemiology, and End Results database. Selected patients were classified into MBC and FBC, of which population demographics and clinicopathological features at baseline were successively extracted for analysis. Comparative analysis was performed to explore the differences in baseline characteristics, followed by propensity-score matching to calibrate the objective distinctions for adjusted analysis. Survival analysis was carried out to investigate divergences presented in prognosis from the two cohorts, and risk factors for prognosis were successively identified using univariate and multivariate COX regression analyses. RESULTS: A total of 407341 individuals were eligible, including 3111 MBC (0.7%) and 404230 FBC (99.3%) patients. Comparatively, patients with MBC tended to be older at diagnosis, with a higher confirmation of ductal carcinoma, a higher histological grade, a higher TNM stage, a higher proportion of luminal-like subtype, a higher rate of lung metastasis, a lower incidence of liver involvement, and a lower rate of surgical, radiation, and chemotherapeutic delivery. The overall prognosis of MBC was significantly worse than that of FBC, with a decreasing divergence both in median overall survival (65.5 months vs. 72.7 months, P<0.0001) and median breast cancer-specific survival (75.4 months vs. 77.8 months, P<0.0001). However, these discrepancies were not consistent among patients from different subgroups stratified by molecular subtype, age at diagnosis, or disease stage. CONCLUSION: In this study, sex-based heterogeneity in clinicopathological characteristics and prognostic profiles was observed in the overall population of patients with breast cancer and was significantly variable among different subgroups. A male-specific design with reasonable endpoints for a clinical trial protocol will be warranted in the future.
PURPOSE: To better understand the differences in clinicopathological features and prognosis between male breast cancer (MBC) and female breast cancer (FBC). MATERIAL AND METHODS: Data on patients diagnosed with breast cancer from January 1, 2010, to December 31, 2016, were obtained from the Surveillance, Epidemiology, and End Results database. Selected patients were classified into MBC and FBC, of which population demographics and clinicopathological features at baseline were successively extracted for analysis. Comparative analysis was performed to explore the differences in baseline characteristics, followed by propensity-score matching to calibrate the objective distinctions for adjusted analysis. Survival analysis was carried out to investigate divergences presented in prognosis from the two cohorts, and risk factors for prognosis were successively identified using univariate and multivariate COX regression analyses. RESULTS: A total of 407341 individuals were eligible, including 3111 MBC (0.7%) and 404230 FBC (99.3%) patients. Comparatively, patients with MBC tended to be older at diagnosis, with a higher confirmation of ductal carcinoma, a higher histological grade, a higher TNM stage, a higher proportion of luminal-like subtype, a higher rate of lung metastasis, a lower incidence of liver involvement, and a lower rate of surgical, radiation, and chemotherapeutic delivery. The overall prognosis of MBC was significantly worse than that of FBC, with a decreasing divergence both in median overall survival (65.5 months vs. 72.7 months, P<0.0001) and median breast cancer-specific survival (75.4 months vs. 77.8 months, P<0.0001). However, these discrepancies were not consistent among patients from different subgroups stratified by molecular subtype, age at diagnosis, or disease stage. CONCLUSION: In this study, sex-based heterogeneity in clinicopathological characteristics and prognostic profiles was observed in the overall population of patients with breast cancer and was significantly variable among different subgroups. A male-specific design with reasonable endpoints for a clinical trial protocol will be warranted in the future.
Authors: Shusma C Doebar; Leen Slaets; Fatima Cardoso; Sharon H Giordano; John Ms Bartlett; Konstantinos Tryfonidis; Nizet H Dijkstra; Caroline P Schröder; Christi J van Asperen; Barbro Linderholm; Kim Benstead; Winan Nm Dinjens; Ronald van Marion; Paul J van Diest; John Wm Martens; Carolien Hm van Deurzen Journal: Mod Pathol Date: 2017-01-13 Impact factor: 7.842
Authors: Suparna Wedam; Lola Fashoyin-Aje; Erik Bloomquist; Shenghui Tang; Rajeshwari Sridhara; Kirsten B Goldberg; Marc R Theoret; Laleh Amiri-Kordestani; Richard Pazdur; Julia A Beaver Journal: Clin Cancer Res Date: 2019-10-24 Impact factor: 12.531
Authors: Michael J Hassett; Mark R Somerfield; Elisha R Baker; Fatima Cardoso; Kari J Kansal; Dylan C Kwait; Jennifer K Plichta; Charité Ricker; Anna Roshal; Kathryn J Ruddy; Joshua D Safer; Catherine Van Poznak; Rachel L Yung; Sharon H Giordano Journal: J Clin Oncol Date: 2020-02-14 Impact factor: 44.544
Authors: Xiaoxian Li; Jing Yang; Uma Krishnamurti; Lei Huo; Kevin C Ward; Ruth O'Regan; Limin Peng Journal: Clin Breast Cancer Date: 2017-04-28 Impact factor: 3.225
Authors: Mary Pritzlaff; Pia Summerour; Rachel McFarland; Shuwei Li; Patrick Reineke; Jill S Dolinsky; David E Goldgar; Hermela Shimelis; Fergus J Couch; Elizabeth C Chao; Holly LaDuca Journal: Breast Cancer Res Treat Date: 2016-12-22 Impact factor: 4.872
Authors: Anne Marie Bak Jylling; Vibeke Jensen; Giedrius Lelkaitis; Peer Christiansen; Sarah Schulz Nielsen; Marianne Djernes Lautrup Journal: Breast Cancer Date: 2020-02-27 Impact factor: 4.239